FDA Approves First Treatment for Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) was granted accelerated approval for the treatment of adult patients with noncirrhotic nonalcoholic steatohepatitis (NASH).